All In Biotech

Drug Trial Radar · NCT03873987

Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients

A Randomized, Open-label, PK and Safety Study to Evaluate the Relative Exposure and Safety of a New Formulation vs the Approved Formulation of a Single 1200 mg IV Dose of ORBACTIV® (Oritavancin) in Subjects Being Treated for ABSSSI

Last checked: Nov 19, 2026Latest source record: Apr 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

Jul 16, 2019

Primary completion

Aug 27, 2019

Study completion Sep 4, 2019

Sponsor

Lead sponsor
Melinta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the pharmacokinetic (PK) and safety of Kimyrsa versus the approved oritavancin formulation in subjects with acute bacterial skin and skin structure infection (ABSSSI). Kimyrsa adjusts the infusion time, concentration and reconstitution/administration solutions of a single 1200 mg intravenous (IV) infusion of oritavancin

Conditions

  • Acute Bacterial Skin and Skin Structure Infection

Interventions

  • Current Formulation of OritavancinDrug

    Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)

  • KimyrsaDrug

    New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative Exposure of AUC of the New Formulation to the Approved FormulationTime frame: 72 hours
  2. Relative Exposure of AUC of the New Formulation to the Approved FormulationTime frame: 168 hours (Day 8)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • ML-ORI-102 Study Site

    Chula Vista, California

  • ML-ORI-102 Study Site

    La Mesa, California

  • ML-ORI-102 Study Site

    Burr Ridge, Illinois

  • ML-ORI-102 Study Site

    Somers Point, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.